Skip to main content

Table 1 Patient characteristics

From: Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy

Variables

No. (%)

Age

 Median

68 (37–90)

Sex

 Male

120 (69)

 Female

54 (31)

ECOG

 0

8 (4.6)

 1

132 (75.9)

 2

26 (14.9)

 3

8 (4.6)

Primary site

 Renal pelvis

87 (50)

 Ureter

77 (44.3)

 Pelvis and ureter

10 (5.7)

Multifocality

 No

151 (86.8)

 Yes

23 (13.2)

Tumor size

 Median (cm)

4.1 (0.3–18.0)

Grade

 Low

8 (4.6)

 High

144 (82.8)

 NA

22 (12.6)

Lymphovascular invasion

 Negative

83 (47.7)

 Positive

50 (28.7)

 NA

41 (23.6)

Perineural invasion

 Negative

112 (64.3)

 Positive

21 (12.1)

 NA

41 (23.6)

PD-L1

 Negative

36 (20.7)

 Positive

7 (4)

 NA

131 (75.3)

Initial stage

 0a

2 (1.1)

 0is

2 (1.1)

 I

18 (10.3)

 II

19 (11)

 III

52 (29.9)

 IV

77 (44.3)

 NA

4 (2.3)

Present disease status

 Initially diagnosed

8 (4.6)

 Local recurrence only

56 (32.2)

 Distant metastasis only

59 (33.9)

 Local recurrence and distant metastasis

51 (29.3)

Interval between diagnosis and first recurrence

 Median (month)

8 (1–106)

Surgery

 Radical nephroureterectomy

135 (77.6)

 Ureter segmental resection/Nephrectomy

8 (4.6)

 LN dissection only

1 (0.6)

 Biopsy only

15 (8.6)

 No

15 (8.6)

Resection margin (n = 144)

 Negative

94 (65.3)

 Close

25 (17.3)

 Positive

18 (12.5)

 NA

7 (4.9)

Chemotherapy at radiotherapy

 Yes

101 (58)

 No

73 (42)

Immunotherapy at radiotherapy

 Yes

19 (10.9)

 No

155 (89.1)

Aim of radiotherapy

 Salvage

73 (42)

 Palliative

101 (58)

Radiotherapy method

 2D/3D

61 (35.1)

 IMRT

113 (64.9)

Total dose

 Median (Gy)

45 (range, 15–65)

Fractional dose

 Median (Gy)

2.65 (range, 1.65–20)

  1. NA not available, PD-L1 programmed death-ligand 1, 2D 2-dimensional RT, 3D 3-dimensional RT, IMRT intensity modulated radiotherapy